Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
马萨诸塞州剑桥，2024年11月22日（环球资讯网）—— Seres therapeutics公司（纳斯达克：MCRB），一家领先的现场生物治疗公司，今天宣布首席执行官埃里克·沙夫将于2024年12月3日下午4:30参加派杰投资第36届年度医疗健康大会的炉边谈话。
A live webcast of the chat will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at and will be available for replay following the event.
此次聊天的直播网络广播将通过公司网站“投资者与资讯”部分的“活动与演示”标签访问，并将在活动结束后提供重播。
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit .
投资者和媒体联系人：IR@serestherapeutics.com，卡罗·坦齐博士，肯达尔投资者关系公司，ctanzi@kendallir.com，Seres Therapeutics，Inc。
Seres therapeutics公司（纳斯达克：MCRB）是一家临床阶段公司，专注于通过新型现场生物疗法改善医疗脆弱人群的患者结果。Seres成功开发并获批VOWSt，这是第一个获得FDA批准的口服微生物组治疗，并于2024年9月出售给奈斯特健康科学公司。该公司正在开发SER-155，该药在接受异体造血干细胞移植（allo-HSCT）的患者的临床研究中，显示出显著减少血流感染及相关并发症（与安慰剂相比）。SER-155及该公司的其他管线项目旨在针对多种疾病相关途径，并通过培养标准克隆电芯库进行生产，而不是使用VOWSt所用的供体来源生产过程。除了allo-HSCt，该公司还计划在其他医疗脆弱人群中评估SER-155和其他培养的现场生物治疗候选药物，包括自体-HSCt患者、具有中性粒细胞减少症的癌症患者、CAR-T接受者、慢性肝病患者、实脏器移植接受者以及重症监护室和长期急性护理设施中的患者。详情请访问 .
Investor and Media Contacts:
IR@serestherapeutics.com
投资者和媒体联系方式：IR@serestherapeutics.com，卡罗·坦齐博士，肯达尔投资者关系公司，ctanzi@kendallir.com，Seres Therapeutics，Inc。
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
肯达尔投资者关系公司
ctanzi@kendallir.com
ctanzi@kendallir.com
This press release was published by a CLEAR Verified individual.
此新闻发布是由经过验证的个人发布的。
